Research
Hormonal
Erectile dysfunction in diabetic men is strongly associated with cardiovascular disease, often preceding coronary artery disease by 2-5 years, making ED a predictor of cardiac risk.
Erectile dysfunction is not just a sexual problem; it is a warning light for your heart. In diabetic men, ED often appears 2-5 years before heart disease symptoms. If you experience ED, request a cardiovascular risk assessment, as treating the underlying vascular issues can prevent future cardiac events.
GoodSupportsHIGH confidence
ED can precede the onset of coronary artery disease (CAD) by 2–5 years, providing a great opportunity for the early diagnosis of silent CAD and stroke.
Why this rating
Supported by real-world observational data and wide confirmation in literature.
Source
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Giuseppe Defeudis et al. · Diabetes/Metabolism Research and Reviews · 2021
DOI 10.1002/dmrr.3494
narrative_reviewCited 281×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Men with diabetes mellitus have an approximately 3.5-fold higher prevalence of erectile dysfunction compared to men without diabetes, with severity correlating to the duration and complications of the disease.Good
- Testosterone replacement therapy (TRT) improves erectile function and metabolic parameters in hypogonadal diabetic men, but guidelines do not recommend it solely for improving glycemic control.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →